Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

602
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
602
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.0K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.0K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.6K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.6K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

4.4K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
4.4K
Autoimmune Disorders01:29

Autoimmune Disorders

1.9K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.9K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disentangling the Octopus: Strategies to Diagnose and Reduce Assessment Overload.

American journal of pharmaceutical education·2026
Same author

The benefits (or detriments) of adapting to demand disruptions in a hospital pharmacy with supply chain disruptions.

Health care management science·2024
Same author

Longitudinal Measurement of Empathy in Student Pharmacists.

American journal of pharmaceutical education·2021
Same author

The Impact of an Early Clinical Experience on Pharmacy Student Learning About Ambulatory Care Practice.

American journal of pharmaceutical education·2021
Same author

Pharmacy Phamilies as a Component of a Co-Curricular Program for Doctor of Pharmacy Students.

Innovations in pharmacy·2021
Same author

Evaluating pharmacy student use of ExamSoft strength and opportunity reports.

Currents in pharmacy teaching & learning·2020

Related Experiment Video

Updated: Feb 18, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Abatacept.

Burgunda V Sweet1

  • 1College of Pharmacy, University of Michigan, Ann Arbor, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|October 24, 2006
PubMed
Summary
This summary is machine-generated.

Abatacept is a novel selective costimulator modulator for rheumatoid arthritis. It effectively reduces inflammation and symptoms in patients unresponsive to other treatments, including TNF-alpha blockers.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.1K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Related Experiment Videos

Last Updated: Feb 18, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.1K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis involves chronic synovial inflammation driven by activated T cells.
  • Tumor necrosis factor-alpha (TNF-alpha) plays a key role in the inflammatory cascade.
  • Existing treatments like disease-modifying antirheumatic drugs (DMARDs) and TNF-alpha antagonists may be insufficient for some patients.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, indications, efficacy, safety, and administration of abatacept.
  • To discuss the role of abatacept as a selective costimulator modulator in managing rheumatoid arthritis.

Main Methods:

  • Review of existing literature on abatacept.
  • Analysis of clinical trial data evaluating abatacept in rheumatoid arthritis patients.
  • Assessment of abatacept's mechanism of action, focusing on T-cell modulation.

Main Results:

  • Abatacept decreases TNF-alpha and inhibits T-cell function without causing T-cell depletion.
  • Clinical trials demonstrate favorable responses to abatacept in patients with moderate to severe rheumatoid arthritis who inadequately responded to methotrexate or TNF-alpha inhibitors.
  • Combination therapy with abatacept and methotrexate showed improved outcomes.

Conclusions:

  • Abatacept represents a new class of targeted therapy for rheumatoid arthritis.
  • It is indicated for patients with inadequate response to established treatments, including TNF-alpha antagonists.
  • Further postmarketing studies will define its long-term therapeutic role.